The clinical and virological characteristics of severe neonatal echovirus 11 infections

A recent study published within the Eurosurveillance Journal described severe and fatal infections in neonates attributable to a brand new echovirus 11 (E-11) variant in France.

Study: Severe and fatal neonatal infections linked to a brand new variant of echovirus 11, France, July 2022 to April 2023. Image Credit: KomsanLoonprom/Shutterstock.com

Background

Enteroviruses commonly cause infections in newborns. The clinical manifestation ranges from asymptomatic to severe illness or death. Nine neonatal cases of disease with liver failure were reported in France from July 2022 to April 2023.

Seven deaths were reported amongst them. All of them were related to a brand new E-11 variant. In the current study, researchers described the characteristics of this surge in severe neonatal infections.

Case description

The nine cases, all males, from three metropolitan areas in France were admitted to pediatric intensive look after suspected sepsis.

Eight patients were from twin pregnancies, and just one was born at full term from a singleton pregnancy; all were born between 31 and 36 gestational weeks and had been initially hospitalized in neonatology departments before symptom appearance.

The primary symptoms (fever and apnea) appeared three to 5 days after birth. The initial symptoms were rapidly followed by septic shock signs requiring energetic resuscitation.

Acute hepatocellular failure with severe cytolysis was observed in all patients on the day of hospitalization. Quick factor, fibrinogen, and blood coagulation aspects II, V, VII, and X weren’t detectable in all cases.

Patients showed hyperammonemia; three were treated with hemodialysis, five with sodium benzoate, and one succumbed before treatment initiation. Thrombocytopenia was observed in all patients; seven required plasma, platelets, and tranexamic acid.

Two patients showed enterocolitis, three cases had meningoencephalitis, and one had myocarditis. Further, acute renal failure at symptom onset was observed in all cases.

Five patients had normal findings on transfontanelle ultrasonography, whereas two patients showed grade III bilateral intraventricular hemorrhage, and two others had several hyperechogenic lesions within the white matter.

Blood cultures for bacteria were negative inside 48 hours of symptom onset for seven patients. Nevertheless, one patient tested positive for Staphylococcus epidermidis, and one other was positive for Escherichia coli.

The enteroviral genome was detected in all specimens, including cerebrospinal fluid, blood, stool, dried blood spots, post-mortem biopsies, and nasopharyngeal, throat, and rectal swabs. Next-generation sequencing identified E-11 because the causal agent in all cases.

Five moms had gastrointestinal symptoms at or before delivery, and 4 peripartum blood samples were available.

Maternal samples were positive for enterovirus and were later identified as E-11. Empirical antibiotic treatment was began at symptom onset in all patients. Pocapavir was used for treatment in three cases, and polyvalent intravenous immunoglobulins were administered in seven patients.

Of the nine cases, seven patients died between five and 40 days of life. Two patients survived without sequelae.

Molecular characterization and surveillance

The researchers performed phylogenetic analyses of E-11 sequences from samples collected during 2010-23 in France and people from other countries available within the GenBank.

The E-11 strains sequenced in 2022 and 2023 split into two different lineages (1 and a pair of), distinct from pre-2022 E-11 strains. Lineage 1 comprised sequences related to non-neonatal and severe non-severe neonatal infections.

Lineage 2 included the remaining French E-11 sequences from 2022, related to those isolated in 2018-19 in China. A recombinant origin was implicated for each lineages per the similarity plot evaluation.

Greater than 2,000 enterovirus cases were reported in France from January 2022 to April 2023. Of those, 24.5% of patients were newborns, and E-11 was the predominant enterovirus type amongst neonates and non-neonates.

E-11 has been consistently detected in France since April 2022. During 2022-23, 28 neonatal cases exhibited a severe enteroviral infection. Amongst these, 14 cases were identified as E-11.

Against this, 62 severe neonatal cases were documented between 2016 and 2021, and E-11 was detected in 6.2% of cases. Furthermore, male neonates were over-represented amongst severe enteroviral or E-11 cases.

Concluding remarks

Taken together, the study suggests that a brand new E-11 variant related to an increased risk of severe neonatal infection and mortality is circulating in France. Clinicians must be vigilant in regards to the potential involvement of enteroviruses in severe presentations amongst newborns.

Neonates with unexplained sepsis with signs of liver failure (with cytolysis) and myocarditis must be evaluated for enteroviral infection, particularly if the mother had symptoms before delivery, and treatment with pocapavir or immunoglobulins must be considered.